HBM Partners AG

metaLead is an early-stage life science spinout from the University of Zurich, supported by reputable investors, i.e., BaseLaunch. We aim to revolutionize the treatment landscape for metal-related diseases, starting with Wilson disease, leveraging our platform of novel, rationally designed peptides.

Leman Biotech is a clinical-stage biotech company. We are a spin-off of EPFL, dedicated to develop next-generation metabolic cancer immunotherapies. Our exclusive metabolic reprogramming technology reverses T-cell exhaustion, a major bottleneck in cancer immunotherapies.